Earnings
Uber reports 20% revenue growth in fourth-quarter, fueled by food delivery
Uber reported better-than-expected revenue in its fourth-quarter earnings report on Wednesday. Shares sank premarket after the release. Here’s how the company did versus LSEG consensus estimates for the period ended in December: Earnings per share: 71 cents adjusted Revenue: $14.37 billion vs. $14.32 billion estimated Revenue increased from $12 billion a year earlier, Uber said […]
Read More
Eli Lilly blows past quarterly estimates, posts strong outlook as Zepbound and Mounjaro sales soar
Eli Lilly and Company’s logo is displayed during a press conference in Houston, Texas, U.S., Sept. 23, 2025. Antranik Tavitian | Reuters Eli Lilly on Wednesday posted fourth-quarter earnings and revenue and 2026 guidance that blew past estimates, as demand for its blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro soars. The pharmaceutical giant […]
Read More
Yum Brands posts mixed quarter, Taco Bell shines
A customer enters a Taco Bell restaurant in El Cerrito, California, US, on Tuesday, April 29, 2025. David Paul Morris | Bloomberg | Getty Images Yum Brands on Wednesday reported mixed quarterly results, despite strong demand for Taco Bell. Here’s what the company reported for the period ended Dec. 31 compared with what Wall Street […]
Read More
AMD is down 9% after reporting earnings. Here’s why
Chipmaker Advanced Micro Devices (AMD) dropped 9% in early market premarket trading on Wednesday after its first-quarter forecast fell short of some analyst expectations. AMD reported revenue of $10.27 billion for the fourth quarter that topped LSEG consensus estimates of $9.67 billion on Tuesday. The company said it expects $9.8 billion in revenue for the […]
Read More
Novo Nordisk shares tumble 18% as CEO warns it will get worse before it gets better
Just as Novo Nordisk showed signs of a recovery, another cold shower hit investors as the drugmaker surprise pre-released its 2026 forecast late Tuesday, sending shares tumbling. Novo Nordisk’s stock plummeted 18% in Copenhagen early Wednesday, tracking losses seen in its American depositary shares on Tuesday and more than wiping out gains seen so far […]
Read More
UBS beats expectations with $1.2 billion fourth-quarter profit, plans $3 billion buyback
Fabrice Coffrini | AFP | Getty Images UBS announced plans for a $3 billion buyback Wednesday and posted fourth-quarter profits that beat analysts’ forecasts. The Swiss banking giant said it aims to buyback at least $3 billion of shares in 2026, adding that it aims to do more. Net profit attributable to shareholders rose 56% […]
Read More
Match beats estimates, but issues weak guidance due to AI investments
Pavlo Gonchar | SOPA Images | Lightrocket | Getty Images Match Group beat fourth-quarter Wall Street estimates on Tuesday but issued weak guidance as it invests in new artificial intelligence initiatives to turn around declining user growth at Tinder. Shares popped during extended trading. The stock closed 8% lower on Tuesday. Here’s how the company […]
Read More
Chipotle earnings top estimates, but traffic to its restaurants fell again
The New York Stock Exchange welcomes executives and guests of Chipotle (NYSE: CMG) to the podium, on Friday, December 12, 2025, to celebrate the milestone of 4,000 restaurants. To honor the occasion, Scott Boatwright, CEO, joined by Chris Taylor, Chief Development Officer, NYSE, rings The Opening Bell®. Chipotle Mexican Grill on Tuesday reported quarterly earnings […]
Read More
Teradyne stock pops on earnings beat driven by AI demand
Cheng Xin | Getty Images News | Getty Images Teradyne stock popped on Tuesday after the company beat fourth-quarter estimates thanks to strong artificial intelligence demand. The robotics company reported adjusted earnings of $1.80 per share, exceeding the $1.37 per share expected by analysts surveyed by LSEG. Revenue totaled $1.08 billion, topping a forecast of […]
Read More
Merck tops quarterly estimates, posts modest 2026 guidance as generic competition looms
Merck on Tuesday reported fourth-quarter earnings and revenue that topped estimates on strong demand for its cancer immunotherapy Keytruda and some newer products. But the company posted a modest 2026 outlook that fell short of Wall Street’s expectations as it prepares for a few drugs to lose patent protection later this year and face generic […]
Read More